Tekmira: an important upcoming catalyst from ALN-TTR02
While Tekmira (TKMR) is making every effort to advance its own pipeline such as PLK1 and Ebola, investors may forget catalysts from the company's partnered programs. One important upcoming event will be the data release of ALN-TTR02 Phase II trial from partner Alnylam (NASDAQ:ALNY) at the Peripheral Nerve Society Meeting in France on June 30, 2013.
As a reminder, Tekmira has granted a license to Alnylam Pharmaceuticals, Inc. to use Tekmira's lipid nanoparticle (LNP) technology to enable RNAi therapeutic products. Tekmira will receive milestone and royalty payments as these LNP-enabled products are developed and commercialized. ALNY is developing three RNAi therapeutics using Tekmira's LNP technology.
Alnylam has guided that initial
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|